CN117298143A - β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 - Google Patents
β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 Download PDFInfo
- Publication number
- CN117298143A CN117298143A CN202311310846.0A CN202311310846A CN117298143A CN 117298143 A CN117298143 A CN 117298143A CN 202311310846 A CN202311310846 A CN 202311310846A CN 117298143 A CN117298143 A CN 117298143A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- beta glucan
- application
- brain metastasis
- neutrophils
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 title claims abstract description 54
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 54
- 210000004556 brain Anatomy 0.000 title claims abstract description 31
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 30
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 30
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 30
- 206010027476 Metastases Diseases 0.000 title claims abstract description 27
- 230000009401 metastasis Effects 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 229940079593 drug Drugs 0.000 title claims abstract description 6
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 210000000440 neutrophil Anatomy 0.000 claims abstract description 27
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 23
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 230000009257 reactivity Effects 0.000 claims description 3
- 241000222355 Trametes versicolor Species 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 12
- 208000003174 Brain Neoplasms Diseases 0.000 abstract description 11
- 230000000259 anti-tumor effect Effects 0.000 abstract description 11
- 206010059282 Metastases to central nervous system Diseases 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 230000015788 innate immune response Effects 0.000 abstract description 6
- 238000012742 biochemical analysis Methods 0.000 abstract description 5
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000243 solution Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 3
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 3
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 3
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 3
- 238000011503 in vivo imaging Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000005007 innate immune system Anatomy 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000188 beta-D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007106 neurocognition Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
本申请涉及生物技术领域,尤其是涉及一种β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用。本申请在肺癌脑转移模型实验中,证实了β葡聚糖可以激活中性粒细胞,进而达到更好地抗肿瘤效果,并且通过动物实验和血液生化分析的手段证明了经β葡聚糖激活的中性粒细胞也能够有效抑制非小细胞肺癌脑转移瘤的生长。本申请基于β葡聚糖能够调控中性粒细胞的先天免疫能力发挥抗肿瘤能力,且有对抗外周原发肺癌的实验室证据,理论基础可靠。
Description
技术领域
本申请涉及生物技术领域,尤其是涉及一种β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用。
背景技术
脑转移是成人最常见的颅内肿瘤,是全身性癌症最常见、最具破坏性的神经***并发症。肺癌,特别是非小细胞肺癌(NSCLC),是最常见的脑转移原发灶。尽管可以采取手术切除、立体定向放射治疗(SRS)和全脑放射治疗(WBRT)等治疗方式治疗肺癌,脑转移仍会导致不良的神经认知功能、生活质量和预后。因此,对于伴有脑转移的NSCLC患者,迫切需要更有效的治疗方法。
目前治疗脑转移瘤的免疫治疗技术包含免疫检查点抑制剂、靶向中性粒细胞的治疗,以上成为针对原发肺癌的有效治疗手段。当采用免疫检查点抑制剂时,在脑转移瘤治疗上由于考虑血脑屏障通透性差,同时使用类固醇疗效下降,导致临床数据及疗效均为证明完全有效,限制了免疫检查点在非小细胞肺癌脑转移中的研究与应用。
β葡聚糖是包含一组天然存在于谷物、细菌和真菌细胞壁中的β-D-葡萄糖多糖,其物理化学性质因来源而异。其中真菌衍生的β葡聚糖或卡介苗(BCG)能够促进骨髓细胞对继发性感染或炎症产生持续增强的反应,这一过程被称为“训练过的先天免疫”或“先天免疫记忆”,并通过转录组、表观遗传和代谢重编程来介导,目前还没有报道公开β葡聚糖能够应用于抑制肺癌脑转移瘤的生长。
发明内容
本申请的目的在于克服上述现有技术的不足之处而提供一种β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用。本申请应用真菌衍生的β葡聚糖,作用于中性粒细胞,可以有效抑制非小细胞肺癌脑转移瘤的生长。
为实现上述目的,本申请采取的技术方案为:
本申请提供了一种β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用。
本申请发明人经过大量研究及试验发现,β葡聚糖可以通过激活固有免疫***的中性粒细胞,增强了抗肿瘤能力,进而抑制肺癌脑转移瘤生长。
作为本申请所述应用的优选实施方式,所述肺癌为非小细胞肺癌。
本申请在肺癌脑转移模型实验中,证实了β葡聚糖可以激活中性粒细胞,进而达到更好地抗肿瘤效果,并且通过动物实验和血液生化分析的手段证明了经β葡聚糖激活的中性粒细胞也能够有效抑制非小细胞肺癌脑转移瘤的生长。
在一些具体实施例中,β葡聚糖通过向肺癌脑转移模型的腹腔注射,无需脑内原位给药,可操作性强。
作为本申请所述应用的优选实施方式,所述非小细胞肺癌包括HCC827细胞系。
在一些具体实施例中,非小细胞肺癌不仅包括HCC827、A549、PC9细胞系,还包括本领域技术中常见的非小细胞肺癌。
作为本申请所述应用的优选实施方式,将β葡聚糖配制成制剂,在制剂中的β葡聚糖的质量浓度为10mg/ml。
作为本申请所述应用的优选实施方式,所述β葡聚糖调控中性粒细胞反应性上升。
本申请通过应用真菌衍生的β葡聚糖,作用于中性粒细胞,进而有效抑制非小细胞肺癌脑转移瘤的生长。
作为本申请所述应用的优选实施方式,所述制剂还包括PBS溶液。
在一些具体实施例中,所述制剂的配制方法为:将50mg的β葡聚糖粉剂溶解于5mlPBS溶液,β葡聚糖的终浓度为10mg/ml,保存于4℃。
作为本申请所述应用的优选实施方式,所述β葡聚糖来源于真菌。所述真菌包括Trametes versicolor花斑栓菌。
与现有技术相比,本申请具有以下有益效果:
本申请提供了β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用,本申请在肺癌脑转移模型实验中,证实了β葡聚糖可以激活中性粒细胞,进而达到更好地抗肿瘤效果,并且通过动物实验和血液生化分析的手段证明了经β葡聚糖激活的中性粒细胞也能够有效抑制非小细胞肺癌脑转移瘤的生长。本申请基于β葡聚糖能够调控中性粒细胞的先天免疫能力发挥抗肿瘤能力,且有对抗外周原发肺癌的实验室证据,理论基础可靠。
附图说明
图1为实验组和对照组的小鼠体内外周血中性粒细胞计数对比图;
图2为实验组和对照组的小鼠颅内转移瘤的显像对比结果图;
图3为β-Glucan抑制脑脑转移瘤生长结果图。
具体实施方式
为更好的说明本申请的目的、技术方案和优点,下面将结合附图和具体实施例对本申请作进一步说明。
在以下实施例中,所使用的实验方法如无特殊说明,均为常规方法,所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
本申请提供了一种β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用。
β葡聚糖可以通过激活固有免疫***的中性粒细胞,增强了抗肿瘤能力,进而抑制肺癌脑转移瘤生长。
在一些具体实施方式中,所述肺癌为非小细胞肺癌。
本申请在肺癌脑转移模型实验中,证实了β葡聚糖可以激活中性粒细胞,进而达到更好地抗肿瘤效果,并且通过动物实验和血液生化分析的手段证明了经β葡聚糖激活的中性粒细胞也能够有效抑制非小细胞肺癌脑转移瘤的生长。
在一些具体实施例中,β葡聚糖通过向肺癌脑转移模型的腹腔注射,无需脑内原位给药,可操作性强。
在一些具体实施方式中,所述非小细胞肺癌包括HCC827细胞系。
在一些具体实施方式中,非小细胞肺癌不仅包括HCC827细胞系,还包括本领域技术中常见的非小细胞肺癌。
在一些具体实施方式中,将β葡聚糖配制成制剂,在制剂中的β葡聚糖的质量浓度为10mg/ml。
实施例1
1.购置真菌来源的β葡聚糖并进行溶解配制。
配制方法:1支50mg的β葡聚糖粉剂(InvivoGen,货号:tlrl-bgp)溶解于5ml PBS溶液,定终浓度10mg/ml,保存于4℃。
2.立体定向于小鼠中进行非小细胞肺癌脑转移模型构建,可用红色荧光及荧光素酶标记的HCC827细胞系。模型构建前1周给与待建模实验组(β-Glucan)小鼠(6-8周龄)腹腔注射100μl配置好的β葡聚糖,对照组(Normal control,NC)给与等量浓度的DMSO。构建模型当日,在异氟烷气体麻醉下进行操作,减少动物所受痛苦。用麻醉小鼠后,在中线在头皮上切开切口。取前囟(Bregma)点作为原点,向右侧平移2mm,尾侧平移1mm为坐标点,应用磨钻磨出颅骨通道,立体定向针吸取2μl浓度为1×105/μl的肺癌细胞悬液,垂直进入颅骨通道下至3mm,缓慢注入肺癌细胞悬液,停留5分钟后缓慢移除针头。置于保温垫上复苏后放回笼内。
3.每隔一周进行活体成像观察脑内转移瘤动态变化并记录肿瘤大小,给小鼠腹腔注射D-荧光素(Macklin,100μL,浓度为15mg/mL),以对麻醉后JX-594驱动的荧光素酶表达进行成像。使用NightOWL LB 983体内成像***(Berthold,Bad Wildbad,德国)进行体内成像,使用Indigo Image v2.0.5.0软件(Berthold,Bad Wildbad,德国)进行数据采集和分析。4周后取出脑组织在体视荧光显微镜下观察颅内转移瘤的显像结果(如图2所示)。
4.成瘤4周后采小鼠外周血,应用细玻璃管针经眼眶采血,可采约400μl,应用血细胞分析仪进行细胞成分分析,观察中性粒细胞变化情况。
如图1所示,β-Glucan实验组小鼠体内外周血中性粒细胞计数均值高于对照组小鼠体内的外周血中性粒细胞计数均值。经β-Glucan(β葡聚糖)处理后小鼠体内的中性粒细胞反应性上升。
如图3所示,β-Glucan处理组小鼠闹内肿瘤生长相较于对照组缓慢,成瘤率显著下降,下降约25%。提示β-Glucan能够抑制脑内肺癌脑转移瘤生长。
本申请的β葡聚糖是经腹腔注射,无需脑内原位给药,可操作性强;并且调控中性粒细胞的先天免疫能力是其发挥免疫细胞最主要的功能的方面,可行性强,本申请基于β葡聚糖调控中性粒细胞的先天免疫能力发挥抗肿瘤能力,进而有效抑制非小细胞肺癌脑转移瘤的生长。
本申请在以上肺癌脑转移模型实验中,证实了β葡聚糖可以激活中性粒细胞,进而达到更好地抗肿瘤效果,并且通过动物实验和血液生化分析的手段证明了经β葡聚糖激活的中性粒细胞也能够有效抑制非小细胞肺癌脑转移瘤的生长。本申请基于β葡聚糖能够调控中性粒细胞的先天免疫能力发挥抗肿瘤能力,且有对抗外周原发肺癌的实验室证据,理论基础可靠。
最后所应当说明的是,以上实施例仅用以说明本申请的技术方案而非对本申请保护范围的限制,尽管参照较佳实施例对本申请作了详细说明,本领域的普通技术人员应当理解,可以对本申请的技术方案进行修改或者等同替换,而不脱离本申请技术方案的实质和范围。
Claims (9)
1.β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用。
2.如权利要求1所述的应用,其特征在于,所述肺癌为非小细胞肺癌。
3.如权利要求1所述的应用,其特征在于,所述非小细胞肺癌包括HCC827细胞系。
4.如权利要求1所述的应用,其特征在于,将β葡聚糖配制成制剂,在制剂中的β葡聚糖的质量浓度为10mg/ml。
5.如权利要求1所述的应用,其特征在于,所述β葡聚糖调控中性粒细胞反应性上升。
6.如权利要求4所述的应用,其特征在于,所述制剂还包括PBS溶液。
7.如权利要求4所述的应用,其特征在于,所述β葡聚糖来源于真菌。
8.如权利要求4所述的应用,其特征在于,所述真菌包括Trametes versicolor花斑栓菌。
9.如权利要求6所述的应用,其特征在于,所述制剂的配制方法为:将50mg的β葡聚糖粉剂溶解于5mlPBS溶液,β葡聚糖的终浓度为10mg/ml,保存于4℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311310846.0A CN117298143A (zh) | 2023-10-11 | 2023-10-11 | β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311310846.0A CN117298143A (zh) | 2023-10-11 | 2023-10-11 | β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117298143A true CN117298143A (zh) | 2023-12-29 |
Family
ID=89236896
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311310846.0A Pending CN117298143A (zh) | 2023-10-11 | 2023-10-11 | β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117298143A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2637205A1 (en) * | 2006-01-17 | 2007-07-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
CN107106544A (zh) * | 2014-09-19 | 2017-08-29 | 纪念斯隆-凯特琳癌症中心 | 用于治疗脑转移瘤的方法 |
TW201831517A (zh) * | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | 靶向組織蛋白h3肽/mhc複合體之構築體及其用途 |
CA3147575A1 (en) * | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
US20220275371A1 (en) * | 2019-04-23 | 2022-09-01 | Children's Medical Center Corporation | Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb) |
WO2023018941A1 (en) * | 2021-08-13 | 2023-02-16 | University Of Louisville Research Foundation, Inc. | Induction of trained immunity for the treatment of hyperproliferative disorders |
-
2023
- 2023-10-11 CN CN202311310846.0A patent/CN117298143A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2637205A1 (en) * | 2006-01-17 | 2007-07-26 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
CN107106544A (zh) * | 2014-09-19 | 2017-08-29 | 纪念斯隆-凯特琳癌症中心 | 用于治疗脑转移瘤的方法 |
TW201831517A (zh) * | 2017-01-12 | 2018-09-01 | 美商優瑞科生物技術公司 | 靶向組織蛋白h3肽/mhc複合體之構築體及其用途 |
US20220275371A1 (en) * | 2019-04-23 | 2022-09-01 | Children's Medical Center Corporation | Use of rab7 gtpase (rab7) inhibitors in enhancing permeability of the blood brain barrier (bbb) |
CA3147575A1 (en) * | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
WO2023018941A1 (en) * | 2021-08-13 | 2023-02-16 | University Of Louisville Research Foundation, Inc. | Induction of trained immunity for the treatment of hyperproliferative disorders |
Non-Patent Citations (6)
Title |
---|
CHUANLIN DING,等: "Inducing trained immunity in pro-metastatic macrophages to control tumor metastasis", NAT IMMUNOL ., vol. 24, no. 02, 28 February 2023 (2023-02-28), pages 239 - 254 * |
TERESA WM FAN,等: "Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues", ELIFE., 18 August 2021 (2021-08-18), pages 1 * |
于明秀;王凤山;: "酵母β-葡聚糖的提取方法及其生物活性与应用研究进展", 中国生化药物杂志, no. 03, 28 March 2017 (2017-03-28), pages 23 - 27 * |
卜一超,等: "训练免疫在肿瘤综合治疗中的应用研究进展", 中国临床医学, vol. 30, no. 05, 31 May 2023 (2023-05-31), pages 861 - 869 * |
唐明科;孙月明;秦丽娟;贾永森;张田;张伟;: "阿司匹林降低肺癌脑转移及其可能机制研究", 四川大学学报(医学版), no. 06, 15 November 2017 (2017-11-15), pages 54 - 58 * |
路毓峰;常晖;张巍;闫会敏;: "β-葡聚糖对树突状细胞的免疫调节作用及生物学意义", 中国食品卫生杂志, no. 05, 30 September 2015 (2015-09-30), pages 118 - 122 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
Escudero-Jiménez et al. | Cutaneous abscess due to Gordonia bronchialis: case report and literature review | |
CN117298143A (zh) | β葡聚糖在制备治疗肺癌脑转移瘤药物中的应用 | |
CN111437279B (zh) | Huwe1抑制剂bi8626在制备抑制炎症小体激活的药物中的应用 | |
Engquist et al. | Effects of drainage in the treatment of acute maxillary sinusitis | |
EP2663324B1 (en) | Combination therapy for treating prostate cancer | |
US20220323450A1 (en) | Methods and compositions for treating neuroblastoma in a juvenile mammalian body | |
JP2001515761A (ja) | 骨への化学的補給 | |
US11969499B2 (en) | Hydrogel delivery of sting immunotherapy for treatment cancer | |
CN115737830A (zh) | 一种时空差异化诱导肿瘤免疫原性死亡和增强抗原提呈的水凝胶疫苗及其制备方法和应用 | |
US3937816A (en) | Growth regulating compositions extracted from spleen | |
Safonova et al. | Correction of damaging effects of cisplatin-containing polychemotherapy on the intestinal epithelium with Tussilago farfara L. Polysaccharides. | |
Thomas et al. | Field evaluation of efficacy and tolerance of a 2% marbofloxacin injectable solution for the treatment of respiratory disease in fattening pigs | |
RU2658606C1 (ru) | Штамм streptococcus pyogenes n b-7612, продуцент комплекса биологически активных соединений, обладающих иммуностимулирующими свойствами | |
WO2018000975A1 (zh) | 一种防治肿瘤的药物及其用途 | |
EP3923979A1 (en) | Autologous cancer tumour associated extrachromosomal circular dna for use as a therapeutic vaccine | |
Shah et al. | Risk factor for cardiac permanent pacemaker infection | |
CN110559292A (zh) | pifithrin-α在制备放疗辐照后促进皮肤伤口愈合的药物中的应用 | |
Revazova et al. | Stimulation of the growth of human tumor by low-power laser irradiation | |
CN111617235A (zh) | Il-12在术后抗肿瘤方面的应用 | |
CN115350176B (zh) | 一种胃癌肿瘤细胞和胃癌肿瘤干细胞治疗药物及其应用 | |
Wallace | Effect of delayed addition of irradiated cells to small viable tumor inocula | |
Rutka et al. | Gliomas: quo vadis | |
Manwaring | The effects of subdural injections of leucocytes on the development and course of experimental tuberculous meningitis | |
SU65818A1 (ru) | Способ лечени инфекционных болезней |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |